Aedifica SA Overview
Aedifica is a Brussels-based, internally managed healthcare real estate investment trust that owns and develops care homes, senior housing, specialised care properties and other healthcare-related real estate leased on very long contracts to professional care operators across Europe. Over two decades it has grown from a domestic mixed-use REIT into a pan-European healthcare specialist. Its 2026 absorption of Cofinimmo, then Belgium's largest listed REIT, doubled the group to a €12.5bn portfolio and made it Europe's largest listed healthcare-focused real estate company by property value. The model is defensive: rental income is overwhelmingly indexed, occupancy is near 100%, and leases average about 15 years. The investment case rests on structural ageing demographics, an undersupply of modern care beds and a disciplined development pipeline at yields above financing costs. The key tensions are leverage of about 43%, heavy refinancing needs in 2027–28, tenant credit concentration among a few large operators, and the integration of Cofinimmo's legacy office and pub portfolios.
Company's own description
In its standard boilerplate, Aedifica describes itself as a listed Belgian company that provides sustainable real estate to professional operators caring for people with care needs across Europe. It says it specialises in investing in high-quality European healthcare property with a focus on the care needs of elderly people, and that it aims to remain a leader in European listed real estate (company boilerplate, reproduced on investor data platforms, 2025–2026).
After the merger, the H1 2026 report frames the group as "Europe's leading healthcare REIT", with a €12.5bn portfolio of which €11.1bn is healthcare real estate in nine countries (H1 2026 report, 1 Sep 2026).
Independent characterisation
Aedifica is a pure landlord with an integrated development capability. It does not operate care services. Its value chain sits between capital markets (equity, bonds, bank debt) and care operators (commercial, non-profit and public). It creates value through:
-
Acquisitions of standing assets let on long, mostly triple-net, indexed leases.
-
Pre-let development and redevelopment with operators, delivering yields on cost above acquisition yields. The 2025 pipeline of €276m carried an average initial yield on cost of 6.5% (FY2025 results).
-
Asset rotation, selling non-core or weaker assets and recycling capital. €98m was sold in 2024, and the whole Swedish portfolio plus other assets (31 properties, about €105m) was sold in H1 2025 (FY2024 results; H1 2025 report).
-
Capital structure management, keeping debt-to-assets in the low 40s, a low average cost of debt (1.9–2.0%) and high hedging (88% at end-2025, per the FY2025 results presentation).
Revenue model
| Revenue type | Share of revenue | Comment |
|---|---|---|
| Rental income from long leases (healthcare) | ≈100% pre-merger; ≈89% of portfolio value post-merger | Mostly triple-net or double-net leases. In the UK, Finland, Ireland and Germany leases typically run 15–30 years with CPI-linked indexation (often capped or collared). |
| Rental income — offices (legacy Cofinimmo) | Not separately disclosed in retrieved H1 2026 data | Brussels office portfolio inherited from Cofinimmo |
| Rental income — distribution networks / property of distribution networks (legacy Cofinimmo) | Not separately disclosed in retrieved data | Pub portfolio (Pubstone) and insurance agency network (Cofinimur I), inherited from Cofinimmo |
| Development / service income | Immaterial | Developments are capitalised, not sold |
| Product / licensing / subscription | — | — |
Customer types: private care operators (large listed and private groups such as Clariane, emeis and Attendo, which management benchmarks in its H1 2026 slides), regional operators, non-profit and public-sector entities (notably in Finland, Belgium and the Netherlands), and childcare operators (Finland).
End-markets: residential elderly care (nursing homes), assisted living / senior housing, specialised care (mental health, disability), primary care / medical centres (expanded via Cofinimmo), private clinics and rehabilitation (Cofinimmo legacy), childcare centres (Finland), and non-healthcare legacy segments (offices, pubs and insurance agencies).
Strategy
Stated strategy (themes, paraphrased)
-
Healthcare focus: investment exclusively in European healthcare real estate, centred on elderly care (company boilerplate).
-
Creating Europe's leading healthcare REIT through the Cofinimmo combination, with scale, diversification, cost synergies and cost-of-capital benefits (H1 2026 report).
-
Pre-let development as the engine of organic growth at yields on cost above the portfolio yield (6.5% average on the 2025 pipeline).
-
Asset rotation: disciplined disposal of non-core or underperforming assets (Sweden exit; €110m target for 2026).
-
Balance-sheet discipline: debt-to-assets around 42–43%; diversified funding; BBB+ rating.
-
Sustainability: net-zero ambition for the portfolio by 2050, EPC coverage, and support for operators in reducing portfolio emissions (Q3 2025 slides).
Initiatives in the last 24 months
| Initiative | Timing | Detail / target | Status |
|---|---|---|---|
| Cofinimmo combination | May 2025 to Jul 2026 | All-share exchange offer followed by legal merger | Completed 1 Jul 2026 |
| Synergy programme | 2026–2027 | At least €16m annual run-rate synergies during 2027; about €5–5.5m impact in 2026 | In progress (H1 2026) |
| Integration | 2,026 | Country leads appointed, IT harmonised, single platform | In progress |
| Competition-remedy divestments | Several years from 2026 | About €300m of Belgian healthcare real estate to be sold | Commitment (BCA clearance, Jan 2026) |
| Asset rotation 2026 | 2,026 | €110m target; €54m achieved by H1 | In progress |
| Investment programme | Ongoing | €531m programme at 30 Jun 2026; €195m new investments announced YTD (€84m in H1 plus €111m over summer) | Ongoing |
| Refinancing | 2,026 | €620m inaugural syndicated facility for the combined group; €930m of long-term bank (re)financing contracted in H1 2026 | Completed in H1 2026 |
| Development pipeline target | Medium term | €500–750m pipeline ambition (per H1 2026 earnings call summary, Investing.com) | Target |
| Strategic review of non-healthcare assets | n/v | Offices and distribution networks inherited from Cofinimmo | Not formally announced in retrieved sources |
Guidance / medium-term targets
| Item | Target | Source |
|---|---|---|
| FY2026 rental income | ≈€656m | H1 2026 earnings summary (Quartr) |
| FY2026 EPRA Earnings | €436m | H1 2026 report |
| FY2026 EPRA EPS | €5.35 (+4% on FY2025's €5.15) | H1 2026 report |
| FY2026 gross DPS | €4.20 (+5%) | Q1 and H1 2026 reports |
| Year-end 2026 debt-to-assets | ≈42% | H1 2026 earnings summary |
| Leverage corridor | 42–43% | H1 2026 call summary |
| Synergies | ≥€16m run-rate during 2027 | H1 2026 report |
Pre-merger standalone guidance for FY2026 had been EPRA EPS of €5.20 (FY2025 results, Feb 2026). The upgrade to €5.35 reflects merger accretion.
Products & Services
Aedifica's "products" are real estate asset classes and lease formats. The catalogue below follows the company's facility-type and country segmentation.
Healthcare real estate
| Product line | Description | Target customer | Lease / pricing model | Geography | Flagship / notes |
|---|---|---|---|---|---|
| Elderly care homes (nursing homes) | Purpose-built residential care facilities with 24/7 nursing | Commercial and non-profit care operators | Long triple-net leases (often 20–30 years in DE/UK/IE; 27-year emphyteutic or long leases in BE), CPI-indexed | All 9 countries | Core of the portfolio; with senior housing ≈86% of assets (FY2024) |
| Senior housing / assisted living | Independent apartments with optional care services | Operators; in some NL assets, residents directly (B2C model) | Long leases; some B2C rents in NL | BE, NL, DE, FI | NL shift towards B2C lifted rents in 2025 (FY2025 webcast) |
| Specialised care properties | Facilities for mental health, disability and care for people with special needs | Public and non-profit operators | Long leases | FI, UK, NL, BE | Expanded via Hoivatilat (Finland) |
| Childcare / day-care centres | Children's day-care buildings | Municipal and private childcare operators | Long leases | FI | Inherited with Hoivatilat |
| Primary care / medical office (legacy Cofinimmo) | Medical centres, GP practices and outpatient facilities | Healthcare providers | Long leases | BE, NL, IE, others | Via Cofinimmo (n/v detail) |
| Clinics and rehabilitation centres (legacy Cofinimmo) | Acute and post-acute clinics, rehab and psychiatric clinics | Hospital and clinic operators | Long leases | DE, FR, BE, NL | Via Cofinimmo (n/v detail) |
| Development and redevelopment programme | Pre-let new builds and extensions delivered to operators | Existing and new tenants | Yield on cost about 6.5% (2025 pipeline average) | All markets | €531m investment programme at 30 Jun 2026; €195m of new investments announced YTD to summer 2026 |
Non-healthcare (legacy Cofinimmo, post-1 July 2026)
| Product line | Description | Tenant / partner | Status |
|---|---|---|---|
| Offices (Brussels) | Office buildings mainly in Brussels CBD and decentralised areas | Corporate and public tenants | Non-core to Aedifica's healthcare strategy; strategic intent (hold, reposition or sell) not explicitly confirmed in retrieved sources |
| Pubstone | Pub estate in Belgium and the Netherlands leased to a brewer (AB InBev group) | Brewer (single-tenant master lease) | Legacy distribution network; n/v current treatment |
| Cofinimur I | Insurance agency branch network in France | Insurer (MAAF/Covéa group) | Legacy distribution network; n/v current treatment |
Financial "products" (capital-markets offering)
Aedifica shares (BEL 20), an optional stock dividend programme offered in past years, sustainability bonds and US private placement notes (including £180m USPP in 2021), and commercial paper backed by A-2 short-term rating (2026).
Financial Narrative
Sources: FY2021 and FY2022 annual results releases (23 Feb 2022; 16 Feb 2023); FY2024 annual results (19 Feb 2025); Aedifica website consolidated accounts (FY2023–FY2025 income statement; FY2022–FY2025 balance sheet), published 16 Feb 2026. All figures are in EUR millions unless stated. FY = calendar year.
Income statement
Notes:
-
The FY2024 release reports €234.6m as +7% year on year, which implies about €219m for FY2023.
-
The FY2022 EPRA NTA restatement is noted in 6.4.
-
2021 EPRA EPS of €4.35 compares with €4.23 for the 2020 period.
Margins and growth
Rental income CAGR FY2021–FY2025: about 11.7% per year (derived: €232.1m to €361.0m over four years).
EPRA EPS CAGR FY2021–FY2025: about 4.3% per year (derived).
Commentary. Growth decelerated sharply from high teens in 2022–2023 to about 7% in 2024–2025. The early years were driven by large acquisition and development volumes (more than €800m invested in 2022). The later slowdown reflects a deliberate pivot, after interest rates rose in 2022–23, from external growth to asset rotation and balance-sheet protection. Like-for-like growth has stepped down from 4.2% (2022, peak inflation indexation) to 2.7% (2025) as CPI cooled.
Margins expanded consistently: the EPRA cost ratio fell from 15.4% to 13.5% between 2023 and 2025 because overheads stayed flat in absolute terms (€35.7m to €34.7m) while rents rose about 15%.
EPRA EPS dipped in 2024 (-1.8%), the only decline in the series. The cause was dilution from the 2023 capital increase (share capital rose from €1,006.9m to €1,203.6m in 2023) and higher interest costs, before growth resumed in 2025.
IFRS net profit is highly volatile because of non-cash revaluations. 2022 was boosted by property and hedge revaluations (€331.8m). 2023 almost wiped out IFRS earnings (€24.5m) on a €143.6m property devaluation and €50.9m of negative hedge revaluation. 2024–2025 recovered as valuations stabilised and then rose (+€75.4m in 2025).
The 2025 tax line jumped to €38.6m, mainly deferred tax on foreign revaluations (deferred tax liabilities rose from €133.2m to €159.6m). In addition, a €11.7m loss on disposals in 2025 was associated with the rotation programme, including the Swedish exit.
Balance sheet
Notes:
-
Current "other" financial debt (€484m at end-2025) is largely commercial paper. This explains the structurally negative working capital, which is typical for Belgian REITs and covered by unused committed credit lines (€673m headroom at end-2024).
-
Goodwill (mainly from the Hoivatilat acquisition) has been impaired every year, from €143.7m in 2022 to €59.7m in 2025.
Per-share NAV metrics
Source conflict: the FY2021 release reported an EPRA NTA of €76.05 at 31 Dec 2021, while the FY2022 release shows €72.78 for the same date (and NRV €85.10 versus €88.36; NDV €69.08 versus €72.35). This indicates a restatement of the 2021 comparatives, probably methodological (for example deferred tax treatment). Both values are noted, and the table above uses the originally published figures.
Cash flow
Aedifica has no share buyback programme (none identified). For a REIT with negligible maintenance capex on triple-net assets, EPRA Earnings is the closest proxy for recurring cash generation. Available capital-allocation proxies:
FY2025 divestments included the Swedish exit; H1 2025 disposals were 31 properties for about €105m. The 2026 asset-rotation target is €110m, of which €54m had been achieved by H1 2026 (H1 2026 earnings summary).
Ratios (derived from primary data)
Company-reported figures: net debt/EBITDA of 8.5x (FY2024) and 7.8x (FY2025); interest coverage of 6.2x (FY2024) (MNI note; FY2025 webcast). The cash conversion cycle is not meaningful for a landlord.
Commentary. Recurring returns on equity of about 6.5–6.7% sit close to the EPRA initial yield, which is typical of a moderately geared, core-plus healthcare landlord. The deleveraging from 43.6% debt-to-assets in 2022 to 40.8% in 2025 came alongside rising earnings, so the balance-sheet discipline did not sacrifice growth. Net debt/EBITDA fell below 8x for the first time in the series in 2025.
Post-merger interim figures
Point-in-time metrics:
-
At 31 Mar 2026: EPRA NTA €80.34, EPRA LTV 39.9%, EPRA NIY 5.6%, EPRA vacancy 0.8% (Q1 2026 report, Dutch version).
-
At 30 Jun 2026: EPRA NTA €77.82, after the May 2026 dividend (Saxo, citing H1 2026). EBIT margin 86.6% and average cost of debt 1.9% in H1 2026.
Sources: H1 2025 and H1 2026 reports; Q1 2026 report.
Interpretation. The transaction was EPS-accretive from the first half (+5%) despite issuing about 45 million new shares. Some metrics deteriorated mechanically because the Cofinimmo portfolio is shorter-dated and includes offices: WAULT fell from 18 to 15 years, occupancy from about 100% to 99.1%, EPRA vacancy from 0.1% to 0.8%, and the cost ratio rose to 15.0%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Segment (rental income, EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total group rental income | 314.2 | 338.1 | 361.0 |
Revenue by Segment
| Country (fair value, EUR Mn) | 2021Q1 | 2025 |
|---|---|---|
Belgium | 1,160 | 1,256 |
Germany | 667 | 1,168 |
Netherlands | 534 | 666 |
United Kingdom | 739 | 1,248 |
Finland | 745 | 1,223 |
Ireland | 26 | 432 |
Spain | — | 22 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Rental income (EUR Mn) | 314.2 | 338.1 | 361.0 |
Operating result before result on portfolio (EUR Mn) | 265.8 | 290.3 | 312.1 |
Operating margin (%) | 84.6 | 85.8 | 86.4 |
Rental income YoY growth (%) | — | 7.6 | 6.8 |
Portfolio Component Details
| Portfolio component | Value (EUR Bn, 30 Jun 2026) | Share (%) | Content |
|---|---|---|---|
Healthcare real estate | 11.1 | ≈89 | 924 properties, 80,000+ end users, 9 countries |
Non-healthcare (offices + distribution networks) | ≈1.4 (derived) | ≈11 | Legacy Cofinimmo Brussels offices; Pubstone pub estate (BE/NL); Cofinimur I (FR) |
Group total | 12.5 | 100 | — |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Rental income (EUR Mn) | 232.1 | 273.1 | 314.2 | 338.1 | 361.0 |
Net rental income (EUR Mn) | — | — | 313.0 | 338.0 | 360.5 |
Property operating result — gross profit proxy (EUR Mn) | — | — | 301.7 | 326.2 | 348.6 |
Overheads (EUR Mn) | — | — | 35.7 | 35.1 | 34.7 |
Operating result before result on portfolio — EBITDA proxy (EUR Mn) | — | — | 265.8 | 290.3 | 312.1 |
Change in fair value of investment properties (EUR Mn) | — | — | -143.6 | 15.2 | 75.4 |
Operating result incl. portfolio — EBIT (EUR Mn) | — | — | 95.2 | 275.6 | 348.2 |
Net interest charges (EUR Mn) | — | — | 45.0 | 46.7 | 50.2 |
Change in fair value of financial instruments (EUR Mn) | — | — | -50.9 | -18.7 | -9.6 |
Profit before tax (EUR Mn) | — | — | -3.1 | 205.4 | 283.7 |
Tax expense, negative = credit (EUR Mn) | — | — | -25.6 | 0.3 | 38.6 |
Net profit attributable to owners (EUR Mn) | — | 331.8 | 24.5 | 204.8 | 244.4 |
EPRA Earnings (EUR Mn) | 151.5 | 181.4 | — | 234.6 | 244.8 |
EPRA Earnings per share (EUR) | 4.35 | 4.76 | 5.02 | 4.93 | 5.15 |
IFRS basic EPS (EUR) | — | — | 0.56 | 4.31 | 5.14 |
IFRS diluted EPS (EUR) | — | — | 0.56 | 4.31 | 5.14 |
Gross dividend per share (EUR) | 3.40 | 3.70 | 3.80 | 3.90 | 4.00 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Rental income growth YoY (%) | — | 17.7 | 15.0 | 7.6 | 6.8 |
Like-for-like rental growth (%) | — | 4.2 | — | 3.3 | 2.7 |
Gross margin — property operating result / rental income (%) | — | — | 96.0 | 96.5 | 96.6 |
EBITDA-proxy margin (%) | — | — | 84.6 | 85.8 | 86.4 |
EPRA Earnings margin (%) | 65.3 | 66.4 | — | 69.4 | 67.8 |
Net margin — owners' profit / rental income (%) | — | 121.5 | 7.8 | 60.6 | 67.7 |
EPRA EPS growth YoY (%) | 2.8 | 9.4 | 5.5 | -1.8 | 4.5 |
EPRA cost ratio incl. vacancy (%) | — | — | 15.4 | 14.2 | 13.5 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR Mn) | — | 6,085.5 | 6,176.8 | 6,463.8 | 6,477.1 |
Investment properties (EUR Mn) | — | 5,619.7 | 5,790.4 | 6,117.9 | 6,215.6 |
Assets held for sale (EUR Mn) | — | 84.0 | 58.2 | 100.2 | 69.6 |
Cash and equivalents (EUR Mn) | — | 13.9 | 18.3 | 18.5 | 22.0 |
Non-current financial debt (EUR Mn) | — | 2,017.3 | 1,958.8 | 2,065.2 | 1,933.7 |
Current financial debt (EUR Mn) | — | 435.2 | 321.5 | 448.4 | 551.3 |
Total financial debt (EUR Mn) | — | 2,452.4 | 2,280.3 | 2,513.6 | 2,485.0 |
Net financial debt (EUR Mn) | — | 2,438.5 | 2,262.0 | 2,495.2 | 2,463.0 |
Total equity (EUR Mn) | — | 3,289.3 | 3,580.9 | 3,648.1 | 3,669.3 |
Equity attributable to owners (EUR Mn) | — | 3,282.8 | 3,575.9 | 3,643.0 | 3,663.7 |
Goodwill (EUR Mn) | — | 143.7 | 117.6 | 87.4 | 59.7 |
Intangible assets (EUR Mn) | — | 1.9 | 1.7 | 1.0 | 0.6 |
Deferred tax liabilities (EUR Mn) | — | 164.1 | 138.7 | 133.2 | 159.6 |
Working capital — current assets minus current liabilities (EUR Mn) | — | -392.3 | -280.0 | -355.8 | -485.0 |
Debt-to-assets ratio, regulatory (%) | 42.6 | 43.6 | — | 41.3 | 40.8 |
Real estate portfolio (EUR Bn) | — | 5.7 | — | 6.2 | 6.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansPer-Share Data and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPRA NTA per share (EUR) | 76.05 | 79.71 | 74.18 | 76.63 | 78.40 |
EPRA NRV per share (EUR) | 88.36 | 91.74 | 84.17 | 86.46 | 87.09 |
EPRA NDV per share (EUR) | 72.35 | 83.92 | 75.41 | 77.19 | 77.73 |
EPRA Net Initial Yield (%) | — | 4.9 | 5.3 | 5.3 | 5.6 |
EPRA vacancy rate (%) | 0.5 | 0.4 | 0.1 | 0.1 | 0.1 |
Key Financials and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Development projects delivered (EUR Mn) | — | 295 | — | 297 | 96 |
Divestments (EUR Mn) | — | — | — | 98 | — |
Dividend payout ratio on EPRA EPS (%) | 78.2 | 77.7 | 75.7 | 79.1 | 77.7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE — owners' profit / average owners' equity (%) | — | 0.7 | 5.7 | 6.7 |
ROE on EPRA Earnings — recurring (%) | — | — | 6.5 | 6.7 |
ROA — owners' profit / average assets (%) | — | 0.4 | 3.2 | 3.8 |
Pre-tax ROIC — EBITDA proxy / (equity + net debt) (%) | — | 4.5 | 4.7 | 5.1 |
Current ratio (x) | 0.26 | 0.31 | 0.32 | 0.22 |
Debt / equity (x) | 0.75 | 0.64 | 0.69 | 0.68 |
Net debt / EBITDA proxy (x) | — | 8.5 | 8.6 | 7.9 |
Interest coverage — EBITDA proxy / net interest (x) | — | 5.9 | 6.2 | 6.2 |
Asset turnover — rental income / average assets (%) | — | 5.1 | 5.3 | 5.6 |
Key Financials and Per-Share Data
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Rental income (EUR Mn) | 180.8 | 292.3 |
EPRA Earnings (EUR Mn) | 123.3 | 189.9 |
EPRA EPS (EUR) | 2.59 | 2.71 |
Like-for-like rental growth (%) | 3.0 | 1.7 |
Occupancy (%) | 100.0 | 99.1 |
WAULT (years) | 18 | 15 |
Debt-to-assets (%) | 42.4 | 42.7 |
Real estate portfolio (EUR Bn) | 6.2 | 12.5 |
Key Financials and Per-Share Data (Quarterly)
| Metric | Q1 2025 | Q1 2026 |
|---|---|---|
EPRA Earnings (EUR Mn) | 62.6 | 74.5 |
EPRA EPS (EUR) | 1.32 | 1.32 |
EPRA cost ratio incl. vacancy (%) | 14.1 | 15.0 |
Revenue by Region
| Region (rental income, EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total | 314.2 | 338.1 | 361.0 |
Revenue by Region (%)
| Country (% of portfolio fair value) | 2021Q1 | 2025 |
|---|---|---|
Belgium | 30.4 | 20.3 |
Germany | 17.5 | 18.9 |
Netherlands | 14.0 | 10.8 |
United Kingdom | 19.4 | 20.2 |
Finland | 19.5 | 19.8 |
Ireland | 0.7 | 7.0 |
Region Overview
| Region | Trend | Driver |
|---|---|---|
Ireland | Fastest growing (from €26m in 2021 to €432m in 2025) | New-build nursing homes with long leases into an undersupplied, fragmented market; development pipeline |
Germany | Strong growth (+75% fair value 2021–2025) | Azurit (€245m) and other portfolios; operator stress in the German market has been a watch point |
United Kingdom | Strong growth (+69%) | Bolt-on acquisitions and developments; UK identified as a growth focus in 2024 (MNI) |
Finland | Growth (+64%) | Hoivatilat development engine (care homes, childcare) |
Belgium | Slowest growing / declining share | Mature home market. Post-merger Belgium becomes dominant again (Cofinimmo was Belgium-centric), and the competition remedy requires about €300m of Belgian divestments over several years |
Sweden | Exited (Q1 2025) | Asset rotation: sub-scale, non-core |
Spain | Marginal (€22m) | Small legacy exposure; Cofinimmo adds further Spanish assets |
France and Italy | New since March 2026 | Entered via Cofinimmo |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last close | €62.95 (16 Oct 2026) | Trivano |
52-week range (to Sep 2026) | €59.50 – €80.05 | MarketScreener |
YTD 2026 | ≈-7% (derived from ≈€67.5 at the start of the year) | MarketScreener (-2.5% YTD at €65.80 on 10 Sep 2026) |
1-year / 3-year / 5-year total return | n/v | — |
Valuation Multiples
| Multiple | Aedifica | Basis |
|---|---|---|
P / EPRA Earnings 2026E | 11.8x | €5.35 guidance |
P / EPRA NTA | 0.81x (≈19% discount) | €77.82 NTA at 30 Jun 2026 |
Dividend yield 2026E | 6.7% | €4.20 DPS |
P/E 2026E (IFRS, consensus) | 8.0x | MarketScreener (includes revaluations) |
EV/Sales 2026E | 15.4x | MarketScreener |
EV/EBITDA 2026E | ≈17–18x (derived from EV of about €10.5bn and EBITDA of about €560–570m implied by an ~86% margin on €656m rent) | Derived |
Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Gross DPS (EUR) | 3.40 | 3.70 | 3.80 | 3.90 | 4.00 | 4.20 |
Credit Ratings
| Agency | Long-term | Short-term | Outlook | Date |
|---|---|---|---|---|
S&P Global | BBB+ | A-2 | Stable | Upgraded Mar 2026; reconfirmed in H1 2026 |
Moody's | Not rated | — | — | — |
Fitch | Not rated | — | — | — |
Capital Markets
| Item | Value |
|---|---|
Debt-to-assets | 42.7% (seasonal, after dividend payment) |
Undrawn committed lines | €1,487m |
Average cost of debt including fees | 1.9% |
Long-term bank (re)financing in H1 2026 | €930m, including a €620m syndicated loan |
Maturities 2027–2028 | ≈€2.2bn |
Hedge ratio | ≈88% (end-2025, standalone) |
Encumbered assets | ≈4% of assets (FY2024 standalone) |
Analyst Conclusions
Management guidance (FY2026)
-
EPRA Earnings €436m, or €5.35 per share (+4%)
-
Rental income about €656m
-
DPS €4.20 (+5%)
-
Year-end debt-to-assets about 42%
-
Synergies of €5–5.5m in 2026, reaching at least €16m run-rate during 2027
MarketScreener's forward data imply a 2027 dividend yield of about 6.5% at September prices, consistent with mid-single-digit DPS growth.
Bull case
-
Full-year synergies plus mechanical consolidation drive another step-up in 2027 EPRA EPS. €16m of synergies alone is roughly €0.17 per share on about 92.6m shares (derived), or about 3% accretion, before pipeline growth.
-
NAV discount compression. At about 0.81x EPRA NTA and a 6.7% yield, the stock prices in a negative scenario that is inconsistent with 99% occupancy, a 15-year WAULT and a BBB+ balance sheet.
-
Non-core disposals (offices, pubs, the €300m remedy) executed near book value would cut leverage towards 40%, make the portfolio purely healthcare, and could support re-rating to peer premiums.
Bear case
-
Refinancing at higher rates. Rolling about €2.2bn of 1.9% debt in 2027–28 into a higher-rate environment could erase much of the synergy gain.
-
Operator stress. Margin pressure at large European operators could force rent cuts or re-lettings, especially in the UK, Germany and France.
-
Disposal and valuation risk. Forced Belgian sales and a weak office market could lead to book losses and higher LTV. The 2023 experience showed how quickly valuations can move (-€143.6m in one year).
Key catalysts and monitorables (next 12 months)
| Date / period | Catalyst |
|---|---|
| 18 Nov 2026 | Q3 2026 results: synergy tracking, leverage, rent cover |
| Feb 2027 | FY2026 results and FY2027 guidance (first full combined year) |
| 2,027 | Progress on refinancing of the 2027–28 maturities and any bond issuance |
| 2026–27 | Announcement of the office / distribution-network strategy |
| Ongoing | Execution of the €300m Belgian remedy disposals |
| Ongoing | Like-for-like rental growth (1.7% in H1 2026) as indexation fades |
| May 2027 | Payment of the €4.20 dividend |
| Ongoing | ECB rate path and the 10-year Bund yield |
Analyst verdict
Aedifica has spent twenty years building a disciplined, internally managed healthcare property platform. In 2026 it completed the transaction that defines its next decade. The numbers so far support the strategic logic. EPRA EPS rose 5% in the first half despite issuing about 45 million shares, management confirmed guidance of €5.35, and the dividend rises 5% to €4.20. S&P upgraded the credit rating to BBB+, and the group refinanced €930m of bank debt in a single half-year while keeping its average cost of debt at 1.9%. On operating metrics such as cost ratio, margin and occupancy, Aedifica remains best-in-class among European healthcare landlords.
The market's scepticism is nonetheless rational. The shares trade at about 81% of EPRA NTA and about 12x 2026 recurring earnings, and they have fallen about a fifth from their 52-week high. Three questions explain the discount. First, can the 1.9% cost of debt survive the 2027–28 refinancing wall of about €2.2bn? Second, will management convert roughly €1.4bn of non-healthcare legacy assets and €300m of mandated Belgian disposals into capital without value leakage? Third, are tenant rent covers robust enough for a sector whose largest operators remain under financial pressure?
Our assessment is that Aedifica's lease security (15-year WAULT, 99% occupancy, CPI indexation) and its scale-driven synergies give it more room to absorb higher refinancing costs than the valuation implies. The 6.7% prospective yield is well covered by a payout of about 78%. The investment case therefore hinges less on growth than on execution: delivering the €16m synergy run-rate, presenting a credible non-core disposal plan, and keeping leverage within the 42–43% corridor. Investors who believe management can do so are being paid a substantial yield while they wait. Those who expect a renewed rise in long-term rates should wait for the FY2026 results and the 2027 refinancing plan before committing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Background | Age | Source |
|---|---|---|---|---|---|
Stefaan Gielens | CEO; Managing / Executive Director; chairs Executive Committee; member of Investment Committee | CEO since 1 Feb 2006; board since 2006 | Master of Law and postgraduate certificate in real estate (KU Leuven); Brussels Bar lawyer 1989–94; KBC Group roles 1994–2005 including Managing Director of Almafin Real Estate and head of real estate management at KBC Bank/KBC Real Estate | Born 1965 (≈61) | Company CV (June 2026) |
Ingrid Daerden | Chief Financial Officer | n/v start date | Financial career in Belgian and international real estate and telecom groups; represented Aedifica on Cofinimmo's board after March 2026 | n/v | Cofinimmo committees page; Aedifica releases (CFO contact) |
Delphine Noirhomme | Investor Relations contact | n/v | — | n/v | Aedifica releases |
Other Executive Committee members | Newly composed Executive Committee effective at the legal merger (1 Jul 2026), combining Aedifica and Cofinimmo executives | From 1 Jul 2026 | — | n/v | Q1 and H1 2026 reports |
Board of Directors
| Name | Role | Since | Notes |
|---|---|---|---|
Jean Hilgers | Independent Chair (from 1 Jul 2026); Chair of the Nomination & Remuneration Committee; member of the Audit & Risk Committee | Board since Mar 2026 | Master in economics (UCLouvain; Chair of its board from 2007); long executive career at the National Bank of Belgium; board roles at the BIS, ING Belgium and AG Insurance; appointed Chair of Wallonie Entreprendre and Cofinimmo in 2025 |
Serge Wibaut | Director; Chair until 30 Jun 2026 | n/v | Remains on the board after handing over the chair |
Stefaan Gielens | Executive Director (CEO) | 2006 | Only executive director on the post-transaction board |
Four further Cofinimmo independents | Independent Directors (co-opted March 2026) | Mar 2026 | Five Cofinimmo directors joined in total under the transaction agreement; names other than Hilgers n/v |
Remaining legacy Aedifica non-executives | Directors | various | n/v |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Free float | ≈98.6% | MarketScreener (Sep 2026) |
Top 10 institutional holders | No controlling shareholder exists. | — |
Insider ownership | Low (single-digit basis points; n/v exact figure) | — |
Competitive Landscape
Key Competitors
| Competitor | Listing / type | Overlap with Aedifica | Relative positioning |
|---|---|---|---|
Care Property Invest | Euronext Brussels REIT | Belgian, Dutch and Spanish care homes | Much smaller; Belgian-centric |
Primary Health Properties (enlarged by combination with Assura in 2025, n/v completion detail) | LSE REIT | UK and Irish primary care | Primary care rather than care homes; adjacent |
Target Healthcare REIT | LSE REIT | UK care homes | Pure UK; smaller |
Impact Healthcare REIT | LSE REIT | UK care homes | Pure UK; smaller |
Welltower | NYSE REIT | UK seniors housing | Global giant; competes for UK assets |
Ventas | NYSE REIT | UK seniors housing | Large; selective UK exposure |
Praemia Healthcare (formerly Icade Santé) | Unlisted vehicle (France) | Clinics, nursing homes in France, Italy, Germany, Spain, Portugal | Major continental competitor for clinic and care assets |
Hemsö | Unlisted (Sweden; listed bonds) | Nordic and German social infrastructure | Strong in the Nordics and Germany |
Primonial REIM / Praemia REIM funds | Unlisted funds | Pan-European healthcare | Large capital pools bidding for assets |
Aberdeen / AXA IM Alts / Swiss Life healthcare funds | Unlisted funds | Pan-European care homes | Capital competitors |
Omega Healthcare / Sabra | NYSE REITs | UK care-home portfolios | US capital competing in the UK |
Peer Comparison FY2025
| Metric (latest FY) | Aedifica | Care Property Invest | Target Healthcare REIT | Welltower |
|---|---|---|---|---|
Revenue | €361.0m (FY2025); ≈€656m guided FY2026 | n/v | n/v | n/v |
Revenue growth | 6.8% (FY2025) | n/v | n/v | n/v |
Operating margin | 86.4% | n/v | n/v | n/v |
R&D intensity | 0% | 0% | 0% | 0% |
Portfolio | €12.5bn (Jun 2026) | n/v | n/v | n/v |



